LearnGlossaryMarketStocksSuperinvestorsSign in

GRFS

Grifols, S.A.

Healthcare · $6.2B market cap

Verdict

Share price

$7.31

close of Oct 3, 2026

Fair value

$10.32

Sticker Price

Payback Price

$4.13

buy price

Undervalued

GRFS is Undervalued: at $7.31 it trades 29% below its fair value of $10.32. Its buy price (Payback Price) is $4.13, 44% below today's price. Business quality is mixed: 2 of 5 key numbers clear the 10% bar.

How we valued it

Free Cash Flow Growth. Reported earnings are shrinking, but free cash flow keeps growing, so we value it on cash flow.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-4.2% a year✗
Equity per share growth8.8% a year✗
Sales growth13.0% a year✓
Free cash flow growth12.5% a year✓
Return on invested capital3.8%✗

Follow GRFS

Get notified when it reaches its buy price of $4.13. Free.

Create a free account

Superinvestors

None of the investors we track holds GRFS right now. In Q2 2026, 1 sold out. Who we track

Moves in Q2 2026

Sold out: Bill Nygren

About Grifols, S.A.

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1…

Drug Manufacturers - General

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works